発表論文 (Last update: 22, March, 2024)
→ reserchmap
→ Google scholar
→ 東北大学スカラー
→ Research Gate
→ J-GLOBAL
→ KAKEN

Teruya K*, Oguma A, Iwabuchi S, Nishizawa K, Doh-ura K.
Combination of styrylbenzoazole compound and hydroxypropyl methylcellulose enhances therapeutic effect in prion-infected mice.
Molecular Neurobiology, 2023. online published 20 December 2023
doi: 10.1007/s12035-023-03852-4



Okawara A, Hada K, Kurotani R, Teruya K, Konno H*.
Design of the peptide C-terminus protecting group and application for the peptide fragment coupling reaction.
Tetrahedron Letters, 127, 154665, 2023.
doi: 10.1016/j.tetlet.2023.154665



Kai H, Teruya K, Takeuchi A, Nakamura Y, Mizusawa H, Yamada M, Kitamoto T*.
Preventive or promotive effects of PRNP polymorphic heterozygosity on the onset of prion disease.
Heliyon, 9, e13974, 2023.
doi: 10.1016/j.heliyon.2023.e13974



Teruya K, Oguma A, Takahashi S, Watanabe-Matsui M, Tsuji-Kawahara S, Miyazawa M, Doh-ura K*.
Anti-prion activity of cellulose ether is impaired in mice lacking pre T-cell antigen receptor α, T-cell receptor δ, or lytic granule function.
International Immunopharmacology 107, 108672, 2022.
doi: 10.1016/j.intimp.2022.108672



Awahara C, Oku D, Furuta K, Kobayashi K, Teruya K, Akaji K, Hattori Y*.
Effects of side-chain configurations of a retro-inverso type inhibitor on the human T-cell leukemia virus (HTLV)-1 protease.
Molecules 27, 1646, 2022.
doi: 10.3390/molecules27051646



Teruya K*, Iwabuchi S, Watanabe Y, Tsuchida R, Watanabe-Matsui M, Konno H, Doh-ura K.
Activities of curcumin-related compounds in two cell lines persistently infected with different prion strains.
Biochimica et Biophysica Acta (BBA) - General Subjects 1866, 130094, 2022.
doi: 10.1016/j.bbagen.2022.130094



Ding M, Teruya K, Zhang W, Lee HW, Yuan J, Oguma A, Foutz A, Camacho MV, Mitchell M, Greenlee JJ, Kong Q, Doh-ura K*, Cui L*, Zou WQ*.
Decrease in Skin Prion-Seeding Activity of Prion-Infected Mice Treated with a Compound Against Human and Animal Prions: a First Possible Biomarker for Prion Therapeutics.
Molecular Neurobiology 58, 4280-4292. 2021.
doi: 10.1007/s12035-021-02418-6



Teruya K, Oguma A, Arai K, Nishizawa K, Iwabuchi S, Watanabe-Matsui M, Sakasegawa Y, Schatzl H, Gilch S, Doh-ura K*.
Polymorphisms in glia maturation factor β gene are markers of cellulose ether effectiveness in prion-infected mice.
Biochemical and Biophysical Research Communications 560, 105-111. 2021.
doi: 10.1016/j.bbrc.2021.04.116



Nishizawa K, Teruya K, Oguma A, Sakasegawa Y, Schatzl H, Gilch S, Doh-ura K*.
Preparation and Characterization of Cellulose Ether Liposomes for the Inhibition of Prion Formation in Prion-infected Cells.
Journal of Pharmaceutical Sciences, 108: 2814-2820. 2019.
doi: 10.1016/j.xphs.2019.03.025



Teruya K, Nishizawa K, Oguma A, Sakasegawa Y, Kitamoto T, Doh-ura K*.
Intermolecular crosslinking of abnormal prion protein is efficiently induced by a primuline-sensitized photoreaction.
Biochimica et Biophysica Acta (BBA) - General Subjects, 1863: 384-394. 2019.
doi: 10.1016/j.bbagen.2018.11.008



Teruya K, Oguma A, Nishizawa K, Kamitakahara H, Doh-ura K*.
Pyrene conjugation and spectroscopic analysis of hydroxypropyl methylcellulose compounds successfully demonstrated a local dielectric difference associated with in vivo anti-prion activity.
PLOS ONE, 12: e0185357, 2017.
doi: 10.1371/journal.pone.0185357



Konno H*, Onuma T, Nitanai I, Wakabayashi M, Yano S, Teruya K, Akaji K.
Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor.
Bioorganic and Medicinal Chemistry Letters, 12: 2746-2751, 2017.
doi: 10.1016/j.bmcl.2017.04.056



Hamanaka T, Nishizawa K, Sakasegawa Y, Oguma A, Teruya K, Kurahashi H, Hara H, Sakaguchi S, Doh-ura K*.
Melanin or melanin-like substance interacts with the N-terminal portion of prion protein and inhibits abnormal prion protein formation in prion-infected cells.
Journal of Virology, 91: e01862-16, 2017.
doi: 10.1128/JVI.01862-16



Teruya K, Oguma A, Nishizawa K, Kawata M, Sakasegawa Y, Kamitakahara H, Doh-ura K*.
A Single Subcutaneous Injection of Cellulose Ethers Administered Long before Infection Confers Sustained Protection against Prion Diseases in Rodents.
PLoS Pathogens, 12: e1006045, 2016.
doi: 10.1371/journal.ppat.1006045



Teruya K*, Hattori Y, Shimamoto Y, Kobayashi K, Sanjoh A, Nakagawa A, Yamashita E, Akaji K.
Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold.
Biopolymers (Peptide Science), 106: 391-403, 2016.
doi: 10.1101/cshperspect.a024430



Hamanaka T, Nishizawa K, Sakasegawa Y, Teruya K, Doh-ura K*.
Structure-activity analysis and antiprion mechanism of isoprenoid compounds.
Virology, 486: 63-70, 2015.
doi: 10.1016/j.virol.2015.09.002



Hamanaka T, Nishizawa K, Sakasegawa Y, Kurahashi H, Oguma A, Teruya K, Doh-ura K*.
Anti-prion activity found in beetle grub hemolymph of Trypoxylus dichotomus septentrionalis
Biochemistry and Biophysics Reports, 3: 332-337, 2015.
doi: 10.1016/j.bbrep.2015.07.009



Hattori Y, Kobayashi K, Deguchi A, Nohara Y, Akiyama T, Teruya K, Sanjoh A, Nakagawa A, Yamashita E, Akaji K*.
Evaluation of transition-state mimics in a superior BACE1 cleavage sequence as peptide-mimetic BACE1 inhibitors.
Bioorganic and Medicinal Chemistry, 23: 5626-5640, 2015.
doi: 10.1016/j.bmc.2015.07.023



Kimura T, Nishizawa K, Oguma A., Nishimura Y, Sakasegawa Y, Teruya K, Nishijima I, Doh-ura K*.
Secretin Receptor Involvement in Prion-Infected Cells and Animals.
FEBS Letters, 589: 2011-2018, 2015.
doi: 10.1016/j.febslet.2015.05.039



Teruya K, Wakao M, Sato M, Hamanaka T, Nishizawa K, Funayama Y, Sakasegawa Y, Suda Y, Doh-ura K*.
Heparinase I-specific disaccharide unit of heparin is a key structure but insufficient for exerting anti-prion activity in prion-infected cells.
Biochemical and Biophysical Research Communications, 460: 989-995, 2015.
doi: 10.1016/j.bbrc.2015.03.139



Katsuyama M, Furuta M, Kobayashi K, Teruya K, Makabe H, Akaji K, Hattori Y*.
Divergent Synthesis of 2,6-Disubstituted Piperidine Alkaloid, (+)-Spectaline by Palladium-Catalyzed Cyclization.
HETEROCYCLES, 91: 959-969, 2015.
doi: 10.3987/COM-15-13172



Ohnishi K, Sakurai H, Katsuyama M, Kobayashi K, Makabe H, Teruya K, Akaji K, Hattori Y*.
Synthesis of a pyrrolidine analog of a tetrahydrofuran containing acetogenin, cis-solamin.
HETEROCYCLES, 91: 573-582, 2015.
doi: 10.3987/COM-14-13163



Shimamoto Y, Hattori Y, Kobayashi K, Teruya K, Sanjho A, Nakagawa A, Yamashita E, Akaji K*.
Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors.
Bioorganic and Medicinal Chemistry, 23: 876-890, 2015.
doi: 10.1016/j.bmc.2014.12.028



Shirai T*, Saito M, Kobayashi A, Asano M, Hizume M, Ikeda S, Teruya K, Morita M, Kitamoto T*.
Evaluating prion models on comprehensive mutation data of mouse PrP.
Structure, 22: 560-571, 2014.
doi: 10.1016/j.str.2013.12.019



Nishizawa K, Oguma A, Kawata M, Sakasegawa Y, Teruya K, Doh-ura K*.
Efficacy and mechanism of a glycoside compound inhibiting abnormal prion protein formation in prion-infected cells: implications of interferon and phosphodiesterase 4D interacting protein.
Journal of Virology, 88: 4083-4099, 2014.
doi: 10.1128/JVI.03775-13



Hattori Y, Kinami G, Teruya K, Nosaka K, Kobayashi K, Akaji K*.
A Practical Synthesis of a Hydroxylated Sesquiterpene Coumarin 10'R-acetoxy-11'-hydroxyumbelliprenin by the regioselective dihydroxylation.
HETEROCYCLES, 87: 423-428, 2013.
doi: 10.3987/COM-12-12636



Teruya K*, Tanaka T, Kawakami T, Akaji K, Aimoto S.
Epimerization in Peptide Thioester Condensation.
Journal of PEPTIDE SCIENCE,18: 669-677, 2012.
doi: 10.1002/psc.2452



Kawahara I, Haruta K, Ashihara Y, Yamanaka D, Kuriyama M, Toki N, Kondo Y, Teruya K, Ishikawa J, Furuta H, Ikawa Y, Kojima C, Tanaka Y*.
Site-specific isotope labeling of long RNA for structural and mechanistic studies.
Nucleic Acids Research, 40: e7, 2012.
doi: 10.1093/nar/gkr951



Akaji K*, Konno H, Mitsui H, Teruya K, Shimamoto Y, Hattori Y, Ozaki T, Kusunoki M, Sanjoh A.
Structure-Based Design, Synthesis, and Evaluation of Peptide-mimetic SARS 3CL Protease Inhibitors.
Journal of Medicinal Chemistry, 54: 7962-7973, 2011.
doi: 10.1021/jm200870n



Unno M, Shinohara M, Takayama K, Tanaka H, Teruya K, Doh-Ura K, Sakai R, Sasaki M, Ikeda-Saito M*.
Binding and Selectivity of the Marine Toxin Neodysiherbaine A, and its Synthetic Analogues, to GluK1 and GluK2 Kainate Receptors.
Journal of Molecular Biology, 413: 667-683, 2011.
doi: 10.1016/j.jmb.2011.08.043



Kakizawa T, Sanjoh A, Kobayashi A, Hattori Y, Teruya K, Akaji K*.
Evaluation of superior BACE1 cleavage sequences containing unnatural amino acids.
Bioorganic Medicinal Chemistry, 19: 2785-2789, 2011.
doi: 10.1016/j.bmc.2011.03.056



Teruya K, Nishizawa K, Doh-ura K*.
Semisynthesis of a protein with cholesterol at the C-terminal, targeted to the cell membrane of live cells.
The Protein Journal, 29: 493-500, 2010.
doi: 10.1007/s10930-010-9278-9



Kimura T, Ishikawa K, Sakasegawa Y, Teruya K, Sata T, Schätzl H, Doh-Ura K*.
GABAA receptor subunit beta1 is involved in the formation of protease-resistant prion protein in prion-infected neuroblastoma cells.
FEBS Letter, 584: 1193-1198, 2010.
doi: 10.1016/j.febslet.2010.02.029



Hizume M, Kobayashi A, Teruya K, Ohashi H, Ironside JW, Mohri S, Kitamoto T*.
Human Prion Protein (PrP) 219K Is Converted to PrPSc but Shows Heterozygous Inhibition in Variant Creutzfeldt-Jakob Disease Infection.
Journal of Biological Chemistry, 284: 3603-3609, 2009.
doi: 10.1074/jbc.M809254200



Nguyen TH, Lee CY, Teruya K, Ong WY, Doh-ura K, Go ML*.
Antiprion activity of functionalized 9-aminoacridines related to quinacrine.
Bioorganic Medicinal Chemistry, 16: 6737-6746, 2008.
doi: 10.1016/j.bmc.2008.05.060



Suzuki SY, Tanaka M, Teruya K, Shinagawa M, Mohri S, Yokoyama T*.
Conformational Changes in Hamster Scrapie Prion Protein (PrP27-30) Associated with Proteinase K Resistance and Prion Infectivity.
Journal of Veterinary Medical Science, 70: 159-165, 2008.
doi: 10.1292/jvms.70.159



Kawasaki Y, Kawagoe K, Chen CJ, Teruya K, Sakasegawa Y, Doh-ura K*.
Orally administered amyloidphilic compound is effective in prolonging the incubation periods of cerebrally infected prion disease animals in a prion strain-dependent manner.
Journal of Virology, 81: 12889-12898, 2007.
doi: 10.1128/JVI.01563-07



Bang JK, Teruya K, Aimoto S, Konno H, Nosaka K, Tatsumi T, Akaji K*.
Studies on Substrate Specificity at PR/p3 Cleavage Site of HTLV-1 Protease.
International Journal of Peptide Research and Therapeutics, 13: 173-179, 2007.
doi: 10.1007/s10989-006-9062-z



Naka H, Teruya K, Bang JK, Aimoto S, Tatsumi T, Konno H, Nosaka K, Akaji K*.
Evaluations of Substrate Specificity and Inhibition at PR/p3 Cleavage Site of HTLV-1 Protease.
Bioorganic and Medicinal Chemistry Letters, 16: 3761-3764, 2006.
doi: 10.1016/j.bmcl.2006.04.056



Bang JK, Naka H, Teruya K, Aimoto S, Konno H, Nosaka K, Tatsumi T, Akaji K*.
Solid-Phase Syntheses of Olefin-Containing Inhibitors for HTLV-1 Protease Using the Horner-Emmons Reaction.
Journal of Organic Chemistry, 70: 10596-10599, 2005.
doi: 10.1021/jo051872s



Teruya K, Murphy CA, Burlin T, Appella E, Mazur JS*.
Fmoc-based Chemical Synthesis and Selective Binding to Super Coiled DNA of the p53 C-terminal Segment and Its Phosphorylated and Acetylated Derivatives.
Journal of PEPTIDE SCIENCE, 10: 479-491, 2004.
doi: 10.1002/psc.552



Akaji K*, Teruya K, Aimoto S.
Solid-Phase Synthesis of HTLV-1 Protease Inhibitors Containing Hydoroxyethylamine Dipeptide Isostere.
Journal of Organic Chemistry, 68: 4755-4763, 2003.
doi: 10.1021/jo030063a



Teruya K, Kawakami T, Akaji K, Aimoto S*.
Total Synthesis of [L40I, C90A, C109A]-Human T-cell Leukemia Virus-type 1 Protease.
Tetrahedron Letters, 43: 1487-1490, 2002.
doi: 10.1016/S0040-4039(02)00040-0



Kawakami T, Hasegawa K, Teruya K, Akaji K, Horiuchi M, Inagaki F, Kurihara Y, Uesugi S, Aimoto S*.
Polypeptide Synthesis Using an Expressed Peptide as a Building Block for Condensation with a Peptide Thioester: Application to the Synthesis of Phosphorylated p21 Max Protein (1-101).
Journal of PEPTIDE SCIENCE, 7: 475-488, 2001.
doi: 10.1002/psc.341



Akaji K*, Teruya K, Akaji M, Aimoto S.
Synthesis of cyclic RGD derivatives via solid phase macrocyclization using the Heck reaction.
Tetrahedron, 57: 2293-2303, 2001.
doi: 10.1016/S0040-4020(01)00113-2



Kawakami T, Hasegawa K, Teruya K, Akaji K, Horiuchi M, Inagaki F, Kurihara Y, Uesugi S, Aimoto S*.
Polypeptide Synthesis Using an Expressed Peptide as a Building Block via the Thioester Method.
Tetrahedron Letters, 41: 2625-2628, 2000.
doi: 10.1016/S0040-4039(00)00232-X



Matsuo H*, Walters KJ, Teruya K, Tanaka T, Gassner GT, Lippard SJ, Kyogoku Y, Wagner G.
Identification by NMR Spectroscopy of Residues at Contact Surfaces in Large, Slowly Exchanging Macromolecular Complexes.
Journal of the American Chemical Society, 121: 9903-9904, 1999.
doi: 10.1021/ja991881g



Otomo T, Teruya K, Uegaki K, Yamazaki T*, Kyogoku Y.
Improved Segmental Isotope Labeling of Proteins and Application to a Larger Protein.
Journal of Biomolecular NMR, 14: 105-114, 1999.
doi: 10.1023/A:1008308128050

Reviews

Konno H, Teruya K
Design, Synthesis and Evaluation of Catechol-Based Amyloid Beta Aggregation Inhibitors.
Heterocycles, 106: 797-818, 2023.
doi: 10.3987/REV-22-999


Teruya K, Doh-ura K.
Therapeutic development of polymers for prion disease.
CELL & TISSUE RESEARCH. 392: 349-365, 2023.
doi: 10.1007/s00441-022-03604-1



Teruya K, Doh-ura K.
Insights from Therapeutic Studies for PrP Prion Disease.
Cold Spring Harbor Perspectives in Medicine. a024430, 2016.
doi: 10.1101/cshperspect.a024430



Kobayashi A, Teruya K, Matsuura Y, Shirai T, Nakamura Y, Yamada M, Mizusawa H, Mohri S, Kitamoto T.
The influence of PRNP polymorphisms on human prion disease susceptibility: an update.
Acta Neuropathologica, 130: 159-170, 2015.
doi: 10.1007/s00401-015-1447-7



Teruya K, Doh-ura K.
Amyloid-binding compounds and their anti-prion potency.
Current Topics in Medicinal Chemistry, 13: 2522-2532, 2013.
doi: 10.2174/15680266113136660178



Kobayashi A, Hizume M, Teruya K, Mohri S, Kitamoto T.
Heterozygous Inhibition in Prion Infection - The Stone Fence Model.
Prion, 3: 27-30, 2009.
doi: 10.4161/pri.3.1.8514



Teruya K, Kawagoe K, Kimura T, Chen C, Sakasegawa Y, Doh-ura K.
Amyloidphilic Compounds for Prion Diseases.
Infectious Disorders Drug Targets, 9: 15-22, 2009.
doi: 10.2174/1871526510909010015



Tanaka Y, Morita EH, Teruya K, Kodama TS, Tanaka T.
Spectroscopic and Theoretical Studies of Biological Macromolecules toward Understanding Molecular Machineries in Life.
Recent Research Development in Physical Chemistry, 9: 1-59, 2007.
ISBN : 8178952599, Record Number : 20093041920, Publisher : Transworld Research Network



Aimoto S, Teruya K, Hasegawa K, Sato T, Akaji K, Kawakami T.
Recent Progress of Thioester Method.
Chemical Research in Chinese Universities, 22: 253-257, 2006.
doi: 10.1016/S1005-9040(06)60091-3

特許等

照屋健太、堂浦克美：
「コンフォメーション病治療用材料、及びその製造方法、並びにコンフォメーション病医薬のスクリーニング方法」
国立大学法人東北大学：
特願2017-169312、2017年9月4日 特開 JP2021004175、2021年1月14日



照屋健太、堂浦克美、西澤桂子：
"Conformational disease prophylactic or therapeutic agent containing inactivated crosslinked oligomer protein, and screening method therefor"
国立大学法人東北大学：
特願WO2018-JP32729　2018年 9月4日、特開 WO2019045116、2019年3月7日



堂浦克美、照屋健太、西澤桂子、小熊歩：
「コンフォメーション病医薬組成物及びその製造方法」
国立大学法人東北大学：
特願2017-093414、2017年5月9日　特開2017-203029、2017年11月16日



北本哲之、堂浦克美、小林篤史、照屋健太、竹内敦子、森田将典、山本幸、白澤映子：
「変異タンパク質の製造方法」
国立大学法人東北大学、株式会社ベネシス：
特願2010-169741、2010年7月28日　特開2011-046698、2011年3月10日



堂浦克美、照屋健太、隅田泰生：
「プリオン病治療薬及びそのスクリーニング方法」
国立大学法人東北大学、国立大学法人鹿児島大学：
特願2007-102005、2007年4月9日　特開2008-281557、2008年11月20日



堂浦克美、照屋健太、竹中茂織、大塚圭一：
「異常型プリオン蛋白質濃縮方法、および除去方法」
国立大学法人東北大学、国立大学法人九州工業大学：
特許4769925
特願2006-071881、2006年3月15日　特開2007-248256、2007年9月27日



竹中繁織、大塚圭一、堂浦克美、照屋健太：
「電気化学的抗原検出法とそのための装置並びに検出チップ」
国立大学法人九州工業大学、国立大学法人東北大学：
特願2006-65744、2006年3月10日　特開2007-240425、2007年9月20日

総説・解説(和文)

照屋健太、堂浦克美
「治療法開発状況」
Clinical Neuroscience, 41(9), 中外医学社　 2023年8月31日発行、1240-1243



照屋健太、堂浦克美
「プリオン病の薬物治療」
脳神経内科, 97(4),　科学評論社　 2022年10月25日発行、467-476



照屋健太、堂浦克美
「プリオン病のアミロイドーシス」
最新アミロイドーシスのすべて　監修: 安東由喜雄、医歯薬出版　 2017年3月15日発行、226-236



照屋健太、堂浦克美
「最新事情　プリオン病のメカニズムと治療戦略」
Medical Bio　オーム社　2010年1月1日発行、48-55



照屋健太、堂浦克美
「プリオン」
KEY WORD 感染症　第２版　先端医学社　2008年8月1日発行、258-259

Protein Data Bank への登録